Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Frontiers in Medicine|January 31, 2024
Case report: abemaciclib-induced syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury in a patient with early-stage estrogen receptor (ER)+ breast cancerNeil Carleton, Julia FoldiCancer Chemotherapy and Pharmacology|June 14, 2023
Pharmacology and pharmacokinetics of elacestrantJan H Beumer, Julia FoldiCurrent Oncology Reports|May 7, 2024
CDK4/6 inhibitors: The Devil is in the DetailTara Magge, Sneha Rajendran, Adam M Brufsky, et al.Protein & Cell|February 15, 2016
RBP-J is required for M2 macrophage polarization in response to chitin and mediates expression of a subset of M2 genesJulia Foldi, Yingli Shang, Baohong Zhao, et al.The Lancet. Oncology|July 4, 2019
Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancersLajos Pusztai, Julia Foldi, Arjun Dhawan, et al.Current Treatment Options in Oncology|July 2, 2021
Optimal Management for Residual Disease Following Neoadjuvant Systemic TherapyJulia Foldi, Mariya Rozenblit, Tristen S Park, et al.Breast Cancer Research : BCR|June 11, 2025
Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United StatesNicole Odzer, Rachel Jaber Chehayeb, Sarah E Schellhorn, et al.Journal of the National Cancer Institute|August 11, 2024
Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trialsJulia Foldi, Neil Carleton, Stewart J Anderson, et al.BMC Cancer|June 30, 2023
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancerJulia Foldi, Anastasia Tsagianni, Max Salganik, et al.Communications Biology|May 20, 2022
A precision medicine approach to metabolic therapy for breast cancer in miceNgozi D Akingbesote, Aaron Norman, Wanling Zhu, et al.Pageof 5